Medisys Technologies, Inc. Appoints Richard Reisner, CPA to Its Board of Directors.Business/Health Editors BATON ROUGE, La. & FAR HILLS, N.J.--(BW HealthWire)--Sept. 27, 2000 Medisys Technologies, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : SCEP SCEP Student Career Experience Program SCEP Simple Certificate Enrollment Protocol (Cisco) SCEP Syndicat Canadien des Communications, de l'Énergie et du Papier (Communications, Energy and Paperworkers Union) ) today announced the appointment of Richard H. Reisner, CPA (Computer Press Association, Landing, NJ) An earlier membership organization founded in 1983 that promoted excellence in computer journalism. Its annual awards honored outstanding examples in print, broadcast and electronic media. The CPA disbanded in 2000. , to its board of Directors. Mr. Reisner comes to Medisys Technologies with extensive background in the medical device industry. In 1992 he co-founded Exogen, Inc. and served as its Vice President and Chief Financial Officer until it was sold to Smith & Nephew, PLC in 1999. Prior to that, Mr. Reisner has held top-level executive management and advisory positions in several public and private companies including Cirrus Diagnostic Inc., Datascope Corp, Pain Suppression Labs, and Electro-Biology Inc. all of which manufactured, marketed and sold medical devices and instruments. Mr. Reisner has been recognized for his acute ability to locate and close on private and venture capital financing To start an own company or to bring a new product to the market, the venture may need to attract financial funding. There are several categories of financing possibilities. If it is a small venture, then perhaps the venture can rely on family funding, loans from friends and has been instrumental in closing several multi-million dollar financing projects, which includes two IPOs. He is a Certified Public Accountant Certified Public Accountant (CPA) An accountant who has met certain standards, including experience, age, and licensing, and passed exams in a particular state. and holds a BS degree from Benjamin Franklin University. "We are confident that Mr. Reisner's long track record of successes along with his wealth of experience and network of contacts will prove invaluable to Medisys and its shareholders as the company begins to commercialize Covertip(TM) during the fourth quarter," commented Edward P. Sutherland, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Medisys Technologies. About Medisys Technologies Medisys Technologies, Inc. is a diversified medical company that develops, manufactures and markets patented products for improving safety and patient care. Spurred by recent Federal Regulations and State Safety Legislation Medisys is currently concentrating on commercializing its suite of patented needle safety technology, with unique features and competitive advantages over other safety devices. In addition to the CoverTip(TM) hypodermic syringe hypodermic syringe n. A syringe with a calibrated barrel, plunger, and tip, used with a hypodermic needle for hypodermic injections and for aspiration. , the Medisys suite of patented safety devices includes: BXDraw(TM), a fine needle biopsy/aspiration safety syringe; SofDraw(TM), a blood and fluid collection safety syringe; and MultiDraw(TM), a needleless multiple vacuum vial blood collection safety device. The Company has a total of 19 patent applications for new safety designs in blood collection, capillary blood testing, and tissue excision cutting needles and has granted 510K clearance by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. to market its products. For more information about Medisys Technology and its proprietary suite of needle safety technologies, please contact Shayne Payne, Juan Dominguez or Dian Griesel, Ph.D. at the Investor Relations Group: 212 736 2650 or visit us on the web at www.medisystech.com Safe Harbor statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: Except for historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including but not limited to economic, competitive, governmental and technological factors affecting the Company's operations, markets, products and prices and other factors discussed in the Company's various filings with the Securities and Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion